← ANALYST RATINGS · TIPRANKS
Erasca (ERAS): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $24.83, the highest $33.00, the lowest $21.00. The average is +85.5% from the last price of $13.39.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $14.50 → $13.50−6.9% | Hold | +0.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $14.00 → $13.00−7.1% | Hold | −2.9% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.50 → $13.50−6.9% | Hold | +0.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $15.50 → $13.50−12.9% | Hold | +0.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $15.00 → $13.50−10.0% | Hold | +0.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $15.50 → $13.50−12.9% | Hold | +0.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $33.00 | Buy | +146.5% | Reiterated | 01.09.26on TipRanks Sep 2 08:05 | −5.6%next day −2.8% · 5 days −6.4% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $20.00 | Hold | +49.4% | Reiterated | 26.08.26on TipRanks Aug 25 07:13 | +0.6%next day +7.8% · 5 days −5.1% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $21.00 | Hold | +56.8% | Assigned | 17.08.26on TipRanks 08:55 | −0.1%next day −0.3% · 5 days −2.5% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $30.00 | Buy | +124.0% | Reiterated | 17.08.26on TipRanks 07:07 | −0.1%next day −0.3% · 5 days −2.5% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $20.00 → $21.00+5.0% | Buy | +56.8% | Reiterated | 12.08.26on TipRanks Aug 13 07:10 | +1.2%next day −4.6% · 5 days −2.3% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $22.00 | Buy | +64.3% | Reiterated | 12.08.26on TipRanks 07:05 | +1.2%next day −4.6% · 5 days −2.3% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $20.00 → $22.00+10.0% | Buy | +64.3% | Reiterated | 12.08.26on TipRanks 06:25 | +1.2%next day −4.6% · 5 days −2.3% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $21.00 → $24.00+14.3% | Buy | +79.2% | Assigned | 14.07.26on TipRanks 16:05 | +8.6%next day −10.0% · 5 days −7.3% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $11.00 → $24.00+118.2% | Buy | +79.2% | Reiterated | 28.04.26on TipRanks 09:25 | −47.8%next day −8.0% · 5 days −0.8% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $11.00 → $20.00+81.8% | Buy | +49.4% | Assigned | 06.03.26on TipRanks Mar 5 17:25 | +0.9%next day +1.0% · 5 days −10.5% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $4.00 → $5.00+25.0% | Buy | −62.7% | Reiterated | 09.12.25on TipRanks 11:00 | −1.1%next day −1.9% · 5 days +7.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Erasca
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $24.12 at a price of $14.66 (+64.6%); now: $24.14 at $13.39 (+80.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 7 | 3 | 3 | 3 |
| Buy | 8 | 3 | 4 | 7 | 7 | 4 |
| Hold | 1 | 0 | 1 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.14 to $-0.09). Last quarter: $-0.14.
Best top-analyst consensus in the sector · Healthcare
About Erasca
- CEO: Jonathan E. Lim
- Employees: 103
- 3115 Merryfield Row, San Diego, CA, 92121, US
- www.erasca.com
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Data from the stock’s TipRanks forecast page, read 11 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗